Precision oncology, activated by light.
Molecular targeting decides where. Light decides when. GenLumina is seeking mission-aligned capital to complete the next preclinical evidence steps while preserving the flexibility to build multiple pharmaceutical partner programmes.
Social Impact Loan
A standardised, unsecured and non-convertible loan for private financiers who want measurable societal impact, fixed interest and no shareholder rights.
Partner PoCs & licensing
Pharma and biotech partners can bring their own antibody, peptide or ligand into a focused PoC. A successful programme can progress through an agreed option toward an indication- and territory-specific licence.
Selective strategic investment
Equity is not the default route. It can be considered when a strategic investor adds meaningful expertise, network access and clinical-development value alongside capital.
Pharma, biotech or medtech partner? Commercial programmes, PoCs, licensing options and future co-development agreements are negotiated separately from financing.
Explore Partnering →Finance the evidence that unlocks partner programmes.
GenLumina does not intend to finance every indication and every clinical programme alone. The current capital supports platform evidence and partner readiness. Partners can then validate the payload with their own targeting biology and advance successful programmes through separately agreed commercial rights.
Platform evidence
Build evidence around targeting, uptake, light activation, safety and tumor-cell killing.
Impact capital
Secure runway and complete the next evidence package without issuing new shares.
Partner PoC
Conjugate and test antibodies, peptides or ligands selected by pharmaceutical partners.
Licence option
A partner can secure an agreed route to commercial rights if the PoC meets defined criteria.
Partner licence
Negotiate indication- and territory-specific development rights while GenLumina retains the underlying platform.
Clinical translation
Advance selected programmes toward regulatory development with partners and specialist capital.
One platform. Multiple commercial programmes.
The underlying GenLumina payload and IP remain a platform. Commercial agreements can therefore be structured around individual partner programmes rather than transferring the entire technology to one company.
PoC first. Licence successful programmes.
A pharmaceutical partner brings its own antibody, peptide or ligand. GenLumina contributes its light-activated payload, conjugation expertise and the focused validation package.
Partner-funded R&D can finance programme validation. Licensing economics, milestones and other commercial terms are negotiated separately for each successful programme.
From tumor imaging to image-guided treatment.
In the clinical phase, GenLumina can work with medtech companies whose imaging systems are already installed in hospitals and used to visualize and localize tumors.
GenLumina contributes payload, activation know-how and IP. A medtech partner can contribute the imaging platform, clinical workflow and device-development capability.
Partner-funded PoCs
Focused research and validation programmes around partner-owned targeting biology.
Programme licences
Rights can be negotiated by indication, application and geographic territory while the core platform remains with GenLumina.
Multiple programmes
The same underlying payload platform can support separate programmes with multiple pharmaceutical and later medtech partners.
Protected platform. Separately licensed programmes.
The IP footprint supports a model in which commercial rights can be structured by programme, indication and geographic territory without transferring ownership of the underlying GenLumina platform.
Different mandates. Clear boundaries.
GenLumina remains a focused payload, platform and licensing company with R&D and project support. Financing should strengthen that model, not force premature dilution or give financiers automatic rights to technology or partner programmes.
Impact loan
Fixed cash interest and a bounded success fee, with no conversion, shares or control rights.
Grants & subsidies
Non-dilutive funding that increases the research value created by private capital.
Pharma partnering
Partner-funded PoCs, licensing options, programme licences and development agreements negotiated separately.
Selective equity
An option, not an assumption—considered only when a strategic investor adds substantial value beyond capital.
Finance the proof partners need.
The round mainly funds studies in living models and the practical development work needed to show that the payload can be delivered safely, activated with light and developed reproducibly.
Safety
Study where the payload travels, how the body handles it and whether it causes unacceptable harm.
Effectiveness
Test whether targeted delivery followed by illumination can slow tumor growth or destroy tumor cells.
Product readiness
Improve dosing, stability, conjugation, quality control and reproducibility.
Partner packages
Translate results into focused PoCs with decision criteria and a defined route toward licensing options.
A loan, not equity.
The current proposal is intentionally simple: one standardised agreement, equal principal terms, no negotiations over individual governance rights and no automatic route onto the cap table.
Societal impact with bounded financial return.
For mission-aligned private financiers who accept preclinical biotech risk and want to help bring light-activated precision oncology closer to patients.
The next financing step remains a choice.
A Series A is not presented as inevitable. If partner-funded PoCs, licences, project funding, milestones and grants can finance indication-specific development, GenLumina can build value without forcing every programme through one large dilutive financing round.
Delay has a human cost.
Every year of delay is another year in which patients cannot benefit from a potentially more controllable way to activate powerful cancer medicines. Private impact financiers can help public and institutional funding move the next Dutch biotech evidence step forward.
First private impact financiers
GenLumina has already attracted approximately €1.1 million through loans, grants and research funding. This round creates a broader group of private financiers alongside those public and institutional sources.
Independence creates leverage
Runway allows GenLumina to generate the evidence needed for partner PoCs and negotiate licensing arrangements from scientific progress rather than short-term cash pressure.
Choose the route that fits your mandate.
Impact financier, institutional investor, foundation, pharmaceutical or medtech partner: GenLumina keeps financing and commercial rights separate while bringing capital and capabilities toward the same objective—light-controlled precision oncology.